SCHEMBL18548554

SCHEMBL18548554

COc1cc2ncnc(Oc3ccc([N+](=O)[O-])cc3F)c2cc1OC

nearest known ligand 0.68

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 2/20 0.68
ABCG2 Q9UNQ0 3/20 0.56
KDR P35968 7/20 0.54
EGFR P00533 3/20 0.54
ACHE P22303 1/20 0.52
BACE1 P56817 1/20 0.52
MET P08581 2/20 0.52
LCK P06239 2/20 0.49
FLT3 P36888 1/20 0.48
RET P07949 1/20 0.47
KIF5B P33176 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28346717 0.92 TRPA1 (0.58) TRPA1ABCG2KDREGFRMET
SCHEMBL28343434 0.90 TRPA1 (0.56) TRPA1ABCG2KDREGFRMET
SCHEMBL31554425 0.84 TRPA1 (0.47) TRPA1ABCG2KDRACHEBACE1
SCHEMBL29487188 0.84 PDGFRA (0.59) KDRMET
SCHEMBL174159 0.84 PDGFRA (0.59) KDRMET
SCHEMBL23142492 0.80 KDR (0.67) TRPA1KDREGFRMETLCK
SCHEMBL30250745 0.80 KDR (0.67) TRPA1KDREGFRMETLCK
SCHEMBL5824789 0.79 TRPA1 (0.76) TRPA1KDREGFRMETLCK
SCHEMBL23749502 0.79 KDR (0.59) TRPA1KDREGFRRET
SCHEMBL371602 0.79 ABCG2 (0.71) ABCG2KDREGFRRETKIF5B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108473434-B Substituted quinolone derivative or pharmaceutically acceptable salt or stereoisomer thereof, and medicinal composition and application thereof 上海海和药物研究开发股份有限公司 2021-11-23 CN disclosed
EP-3339294-B1 QUINOLONE DERIVATIVE, PHARMACEUTICAL ACCEPTABLE SALT, OR STEREOISOMER THEREOF AS AXL INHIBIOTOR SHANGHAI HAIHE PHARMACEUTICAL CO LTD (CN) 2021-04-14 EP disclosed
US-10683278-B2 Substituted quinolone derivatives, or pharmaceutically acceptable salts or stereoisomers thereof, and pharmaceutical compositions and use thereof SHANGHAI HAIHE PHARMACEUTICAL CO., LTD. (CN) 2020-06-16 US disclosed
US-20180265496-A1 SUBSTITUTED QUINOLONE DERIVATIVES, OR PHARMACEUTICALLY ACCEPTABLE SALTS OR STEREOISOMERS THEREOF, AND PHARMACEUTICAL COMPOSITIONS AND USE THEREOF JINAN UNIVERSITY (CN) 2018-09-20 US disclosed
CN-108473434-A Substituted quinolone analog derivative or its pharmaceutically acceptable salt or stereoisomer and its Pharmaceutical composition and application 暨南大学 2018-08-31 CN disclosed
EP-3339294-A1 PHARMACEUTICAL COMPOSITION AND APPLICATION REPLACING QUINOLONE DERIVATIVE, PHARMACEUTICAL ACCEPTABLE SALT, OR STEREOISOMER Jinan University (CN) 2018-06-27 EP disclosed
WO-2017028797-A1 PHARMACEUTICAL COMPOSITION AND APPLICATION REPLACING QUINOLONE DERIVATIVE, PHARMACEUTICAL ACCEPTABLE SALT, OR STEREOISOMER 暨南大学 2017-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180265496-A1 SUBSTITUTED QUINOLONE DERIVATIVES, OR PHARMACEUTICALLY ACCEPTABLE SALTS OR STEREOISOMERS THEREOF, AND PHARMACEUTICAL COMPOSITIONS AND USE THEREOF NRAS, AXL, ABL1 TRPA1 4106/4885ABCG2 309/4885KDR 404/4885
US-10683278-B2 Substituted quinolone derivatives, or pharmaceutically acceptable salts or stereoisomers thereof, and pharmaceutical compositions and use thereof NRAS, AXL, ABL1 TRPA1 4106/4885ABCG2 309/4885KDR 404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.